SENS Stock Risk & Deep Value Analysis
Senseonics Holdings Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About SENS Stock
We analyzed Senseonics Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SENS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SENS Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is continued, heavy cash burn, reflected in Q1 2026's $32.3 million net loss, combined with aggressive expansion. If revenue growth, particularly from the new European direct sales strategy, fails to accelerate sufficiently, the company will face escalating funding needs and could necessitate further significant share dilution from the recently authorized 140,000,000 shares, eroding shareholder value before reaching profitability.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Net loss of $32.3 million in Q1 2026 indicates substantial cash burn.
- ⚠
Stockholders approved increasing authorized common stock to 140,000,000 shares, signaling significant future dilution potential.
- ⚠
HC Wainwright reduced its price target to $14.00, indicating cautious analyst sentiment despite a 'Buy' rating.
- ⚠
High reliance on future market adoption of the Eversense 365-day sensor to offset current unprofitability.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (estimated late August 2026): Failure to meet revenue growth expectations, especially from new European direct sales, could trigger a significant stock sell-off.
- 📅
Further Large-Scale Equity Offering (H2 2026 - H1 2027): Despite recent financing, a substantial capital raise to fund continued expansion, leading to significant shareholder dilution (potential 20%+ share increase).
When to Reconsider
- 🚪
Exit if quarterly revenue growth falls below 40% YoY for two consecutive quarters, signaling a failure in commercialization strategy.
- 🚪
Sell if cash and equivalents drop below $50M, indicating imminent need for highly dilutive financing, or if new equity offerings dilute shares by more than 15% in a single quarter.
- 🚪
Exit if gross margin consistently falls below 50% for two consecutive quarters, suggesting pricing pressure or inefficient operations.
Unlock SENS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Senseonics Holdings Inc (SENS) Do?
Market Cap
$382.65M
Sector
Healthcare
Industry
Medical Devices
Employees
117
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Visit Senseonics Holdings Inc WebsiteInvestment Thesis
If Senseonics effectively executes its direct commercialization strategy in Europe and continues strong adoption of its unique 365-day Eversense CGM, leading to $60M-$62M in FY2026 revenue and accelerating growth into FY2027 ($90M+), then its market cap could re-rate from $0.37B to over $1.5B (4x+) within 3 years, driven by a premium P/S multiple reflecting its differentiated product and growing market share. This is bullish because the market is currently heavily discounting the long-term potential due to present unprofitability and dilution concerns, underestimating the value of the expanding moat and direct commercialization.
Is SENS Stock Undervalued?
Unlock the full AI analysis for SENS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SENS Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$25.00
Bear Case
$4.00
Valuation Basis
Based on 10x Price/Sales multiple applied to estimated FY2027 revenue of $90M and 60M projected diluted shares outstanding.
Entry Strategy
Consider dollar-cost averaging in the $6.50 - $7.50 range, seeking support near previous lows or the 50-day SMA if applicable.
Exit Strategy
Take partial profits at $15.00 and $20.00. Implement a stop-loss order if the stock closes below $5.50 for two consecutive days.
Portfolio Allocation
5% for aggressive risk tolerance, given the company's early-stage and high-volatility nature.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is SENS Financially Healthy?
Valuation
P/E Ratio
-3.32
Forward P/E
-2.10
PEG Ratio
-2.80
Price/Book
8.12
Price/Sales
7.50
Profitability
Gross Margin
52.07%
Operating Margin
-212.95%
Net Margin
-214.16%
Return on Equity
-130.00%
Revenue Growth
71.91%
EPS
$-1.96
Balance Sheet
Current Ratio
4.83
Quick Ratio
4.39
Debt/Equity
0.58
Cash Flow
Operating Cash Flow
-$75.00M
Other
Beta (Volatility)
0.98
Does SENS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The unique 1-year sensor creates significant switching costs once implanted, as patients prefer less frequent replacements. This, combined with proprietary IP and regulatory approvals (intangible assets), provides a durable, though not impenetrable, moat against competitors, which is expanding as the company gains direct control over its commercialization.
Moat Erosion Risks
- •Competitors (Dexcom, Abbott) developing longer-duration or more convenient non-implantable sensors.
- •Reimbursement challenges or slow physician adoption hindering uptake of the implantable technology.
SENS Competitive Moat Analysis
Sign up to see competitive advantages
SENS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Retail sentiment likely mixed, with growth enthusiasm balanced by dilution concerns.
Institutional Sentiment
Positive, but cautious. Analyst consensus is 'Moderate Buy' with an average price target of $17.00, but HC Wainwright's recent target cut to $14.00 shows some tempered expectations.
Insider Activity (Form 4)
MarketBeat reports 4.70% of the stock is owned by company insiders. No specific Form 4 buy/sell activity provided in the last 90 days in the research.
Options Flow
Normal options activity; no unusual put/call ratios or significant block trades were identified in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 for Q2 2026 results.
Surprise Probability
Medium. Strong Q1 growth sets a high bar, but European direct sales integration is a new variable that could lead to volatility.
Historical Earnings Pattern
Stock tends to be highly sensitive to revenue beats/misses and updates on product adoption/regulatory progress, often experiencing double-digit percentage moves.
Key Metrics to Watch
Competitive Position
Top Competitor
DXCM
Market Share Trend
Gaining ground, albeit slowly, with its unique 1-year sensor in a market dominated by larger players like Dexcom and Abbott. Direct European commercialization aims to accelerate this.
Valuation vs Peers
Difficult to compare directly on earnings multiples due to Senseonics' unprofitability. On a P/S basis, SENS is trading at a moderate premium considering its early stage, but a discount if its 10x growth potential is realized.
Competitive Advantages
- •Unique 365-day implantable continuous glucose monitoring (CGM) sensor, reducing patient burden and increasing compliance.
- •Proprietary technology and intellectual property around implantable sensor technology.
- •Direct commercial control in key European markets, offering better market penetration and potentially higher margins.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive SENS Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (estimated late August 2026): Expectation of continued strong revenue growth from European direct sales, exceeding $15M to validate commercialization strategy.
- •Integration of European Commercial Assets (Q3 2026): Successful transition to direct sales in Germany, Spain, Sweden, and Italy, leading to improved gross margins and higher regional market share.
Medium-Term (6-18 months)
- •Expansion of European Direct Sales Footprint (FY2027): Successful replication of direct commercialization model into 2-3 additional high-value European markets, driving 30%+ YoY revenue growth.
- •New Product Iteration/Feature Approval (H1 2027): FDA/CE Mark approval for next-generation Eversense sensor with enhanced features (e.g., smaller size, longer duration beyond 365 days), broadening market appeal.
Long-Term (18+ months)
- •Path to Positive Free Cash Flow (FY2028-FY2029): Achievement of sustained positive operating cash flow, driven by European market leadership and US growth, reducing reliance on dilutive financing.
- •Significant US Market Share Gain (FY2029-FY2030): If Eversense 365-day sensor captures 5-7% of the US CGM market (currently dominated by Dexcom/Abbott), enabling $300M+ in annual revenue.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for SENS?
- ✓
Watch quarterly revenue growth rates; acceleration above 80% YoY indicates strong adoption and commercial execution.
- ✓
Monitor gross margin expansion quarter-over-quarter; sustained improvement towards 65%+ signals improved unit economics.
- ✓
Track cash burn rate; a significant reduction in net loss or a clear roadmap to operating cash flow positivity is critical.
Bull Case Analysis
Sign up free to see the bull case
Competing with SENS
See how Senseonics Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Senseonics Holdings Inc SENS | $382.7M | 6.6 | -3.3 | $11.7M | -214.2% | 71.9% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Dexcom Inc DXCM | $23.8B | 7.0 | 28.4 | $4.7B | 17.9% | 15.6% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Senseonics Holdings Inc Makes Money
Senseonics Holdings Inc. designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its primary product is the Eversense CGM system, which features a unique implantable sensor that provides glucose readings for up to 365 days. The company generates revenue by selling these long-term implantable sensors and their accompanying smart transmitters, primarily through distribution partners and increasingly through its own direct sales force in select international markets. The business model is focused on recurring sensor sales, akin to a subscription, leveraging its differentiated technology to offer a convenient, long-duration monitoring solution.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Senseonics Holdings Inc (SENS)?
As of June 9, 2026, Senseonics Holdings Inc has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Senseonics Holdings Inc?
Senseonics Holdings Inc's market capitalization is approximately $382.7M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Senseonics Holdings Inc use?
SENS is the ticker symbol for Senseonics Holdings Inc. The company trades on the ASE.
What is the risk level for SENS stock?
Our analysis rates Senseonics Holdings Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SENS?
Senseonics Holdings Inc currently has a price-to-earnings (P/E) ratio of -3.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Senseonics Holdings Inc's revenue growing?
Senseonics Holdings Inc has reported revenue growth of 71.9%. The company is showing strong top-line momentum.
Is SENS stock profitable?
Senseonics Holdings Inc has a profit margin of -214.2%. The company is currently unprofitable.
How often is the SENS DVR analysis updated?
Our AI-powered analysis of Senseonics Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SENS (Senseonics Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.